With incidence of cardio-vascular disease growing amongst people on a worldwide scale, it is but natural for pharmaceutical companies to capitalize on the situation by releasing drugs that would combat the disease. To this effect, there are two companies running in the forefront of this race, namely Amgen Inc (NASDAQ:AMGN) which was the first to…
Merck&Co Inc (MRK) And Pfizer Inc (PFE) Team Gears Up To Defeat Cancer
What happens when two world renowned names come together for a cause? This is exactly how a partnership between Merck&Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) can be described as the two giants in the pharmaceutical sector have decided to combine efforts to fight cancer. While Pfizer Inc (NYSE:PFE) has been dedicating its efforts towards…
Allergan Inc (AGN) Sets Date to Decide On Possible Valeant Pharmaceuticals Intl Inc (VRX) Take-Over
Having lost a court battle intended to stall the aggressive proceedings of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Allergan Inc (NYSE:AGN) finally released the date for special meeting of shareholders as being December 18th, 2014. This date is a fall-out of decision of legal law-suit that went against Allergan Inc (NYSE:AGN) and in favor of Valeant…
Kite Pharma Inc (KITE) Shares Skyrocket after Positive Results for Non-Hodgkin’s Lymphoma Drug
In a series of medical advancements, Kite Pharma Inc (NASDAQ:KITE) announced positive results for its anti-CD19 treatment used against aggressive non-Hodgkin’s lymphoma. Following the news, the shares of the company have skyrocketed in after-hours trading with 30% increase in its prices. According to a press release issued by Kite Pharma Inc (NASDAQ:KITE) on August 25, 2014,…
Allergan Inc. (AGN)’s Shareholders Request Special Meeting About The Valeant Pharmaceuticals Intl Inc (VRX)
Allergan Inc. (NYSE:AGN) received written requests from its shareholders who are calling for a special meeting in regards to Valeant Pharmaceutical International Inc.’s intent to acquire Allergan. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Pershing Square Capital Management are chasing Allergan Inc. with a $54 billion deal in hand. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wants Allergan Inc.…
Roche Holding Ltd. (ROG) Ready to Acquire InterMune Inc (ITMN) for $8.3 billion
Roche Holding Ltd. (VTX:ROG) is all set to complete one of the latest pharmaceutical sector deals by acquiring InterMune Inc (NASDAQ:ITMN) for $8.3 billion. Roche Holding Ltd. (VTX:ROG) will pay $74.00 for every single share of InterMune Inc (NASDAQ:ITMN). Both the boards of Roche Holding Ltd. (VTX:ROG) and InterMune Inc (NASDAQ:ITMN) have agreed to a…
Allergan, Inc. (AGN) vs. Valeant Pharmaceuticals Intl Inc (VRX): Losing Ground to Stop Shareholder Meeting
Allergan, Inc. (NYSE:AGN) lost a crucial court bid that could have allowed the company to stop a shareholder meeting planned by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and William Ackman. Ackman joined hands with Valeant in April with a cash-and-stock bid of $54 billion. (You can see entire holdings of William Ackman). Allergan, Inc. (NYSE:AGN) approached…
AstraZeneca plc (AZN) Acquisition: Hard Nut to Crack for Pfizer Inc. (PFE)
In its efforts to cut elevating tax expenses, Pfizer Inc. (NYSE:PFE) has reinitiated its efforts to takeover the London-based first, AstraZeneca plc (LON:AZN). AstraZeneca plc (LON:AZN) can help in cutting tax rates and offer a new drugs pipeline for Pfizer Inc. (NYSE:PFE). However, the cost of acquiring the London-based firm is rising continuously. According to…
Tricolsan Drives Consumers Away From Colgate-Palmolive Co (CL)’s Total Brand
Angela Pollock, who teaches sociology in Knoxville, Tennessee, decided to give up on Total, a brand of Colgate-Palmolive Co (NYSE:CL) after having used it for the last 15 of her 57 years when she heard that it contained triclosan. Having read that this chemical is responsible for arresting growth and triggering carcinoma, she did not…
Company Update: Gilead Sciences, Inc. (NASDAQ:GILD) Submits Japan Approval
TheFlyOnTheWall.com reported this morning that Gilead Sciences, Inc. (NASDAQ:GILD), announced that the company has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, which is a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection. Gilead Sciences, Inc.(NASDAQ:GILD) opened trading today at $82.18 and…